Non-alcoholic fatty liver. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group: The intervention group includes 28 patients. They are randomly placed in this group. They receive 30 grams of sesame oil daily for 12 weeks. The weight loss diet is
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: Willingness to participate in the study Female Being 20 to 50 years old Having Non-alcoholic fatty liver disease Routine consumption of sunflower oil Body mass index between 25 and 40
Exclusion criteria
Exclusion criteria: Participate in other studies in the last 6 months Having weight loss plans in the last three months Having a special diet in the last three months Smoking Being menopausal Having a history of breast cancer Insulin consumption Having allergies Having other liver diseases except non-alcoholic fatty liver Having hereditary hemochromatosis Having serious diseases such as cancer, cholangitis sclerosis, kidney failure, autoimmunity, malignancies, celiac disease Consumption of mineral multivitamin and omega-3 supplements in the past month Consumption of drugs that effects on the level of liver enzymes of ALP, AST and ALT Consumption of drugs that cause fatty liver Using hepatotoxicity drugs Alcohol consumption Pregnancy Lactation Having hormone-dependent cysts Having Wilson's disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fatty liver grade. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Liver sonography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood level of low-density lipoprotein cholesterol. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Medical laboratory (kit).;Blood level of triglyceride. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Medical laboratory (kit).;Blood level of high-density lipoprotein cholesterol. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Medical laboratory (kit).;Blood level of total cholesterol. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Medical laboratory (kit).;Anthropometric indicators. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Medical laboratory (kit).;Blood pressure. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Medical laboratory (kit).;Blood level of insulin. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Medical laboratory (kit).;Blood level of C-Reactive Protein. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Medical laboratory (kit).;Blood level of Malondialdehyde. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Medical laboratory (kit).;Blood level of Fasting Blood Sugar. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Medical laboratory (kit).;Blood level of Alanine Aminotransferase. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Medical laboratory (kit).;Blood level of Aspartate transaminase. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Medical laboratory (kit).;Blood level of Alkaline phosphatase. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Medical laboratory (kit). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMasoumeh Atefi
Esfahan University of Medical Sciences
Outcome results
None listed